Diana Roth O’Brien, MD MPH

Radiation oncologist @MSKCancerCenter, aspiring puppy hoarder | @princeton 08 ➡️ @sunydownstate MD/MPH ➡️ @weillcornell

[Sean McBride @seanmmcbride]

Big congrats to @HimanshuNagarMD on his appointment as our next Chief of External Beam RT for Manhattan and to @LiorBraunstein who will be our inaugural Vice Chair of Clinical AI, Informatics, and Digital Strategy. Their brilliance and skill are huge assets to our department and we're lucky to have 'em! @MSK_RadOnc #radonc

[Daniel Gorovets @DanielGorovets]

We are thrilled to welcome our new residents! What an exceptional group and exciting times ahead. Welcome to @MSK_RadOnc!! ���� #Match2026 #RadOnc #FutureLeaders

[John Cuaron @JohnCuaron]

Hey #radonc!

Trainees seeking an up-to-date treatment guide, attendings interested in learning about MSKCC treatment approaches, and leaders looking to standardize practice across your departments: add this text to your collection! 📖☢️
@LiorBraunstein

https://t.co/qFXWYy4Pmz

[Clin Adv Hem Onc @clinadvances]

“Personalized Approaches to Breast Radiotherapy: Strategies for Treatment Refinement” by Diana A. Roth O’Brien, MD, MPH; and Lior Z. Braunstein, MD https://t.co/SWyDlcg9WB @drothens @LiorBraunstein @MSKCancerCenter

[Diana Roth O’Brien, MD MPH @drothens]

@seanmmcbride @HimanshuNagarMD on speed dial 😉

[Fumiko Ladd Chino, MD, FASCO @fumikochino]

Vegan soul food with these amazing physicians. Thank you to my @MSKCancerCenter colleagues for dinner tonight ...and for your support and friendship over the past 5 years. 🙏🙌❤️ #weekendsinNYC

[Memorial Sloan Kettering Radiation Oncology @MSK_RadOnc]

📢We are overjoyed to announce that Dr @HimanshuNagarMD will be joining @MSKCancerCenter this summer as our Genitourinary Cancer Disease site leader. Dr Nagar is a compassionate clinician & innovative researcher. We are excited to see where he leads our GU #radonc team!

[Memorial Sloan Kettering Radiation Oncology @MSK_RadOnc]

New from @MSKCancerCenter: The optimal tx strategy for anal adenocarcinoma is evolving. This is the 1st report to describe the safety & feasibility of watch & wait in pts who achieved a clinical complete response after neoadjuvant tx for adeno #ancsm
https://t.co/SNFArfHjjU

[Memorial Sloan Kettering Radiation Oncology @MSK_RadOnc]

New in @IJROBP from Dr @drothens @LiorBraunstein & the @MSKCancerCenter #radonc team:
Is #APBI an option for favorable risk #Her2+ #breastCancer?
This study finds excellent short-term local control for HER2+ #bcsm treated with partial breast #radiation
☢️https://t.co/IrUlptpJ6J

[Memorial Sloan Kettering Radiation Oncology @MSK_RadOnc]

By 8 weeks after #APBI, most patients reported resolution of symptoms, with 16% reporting residual moderate symptoms. No ascertained salient dosimetric ☢️ parameters were associated with max symptoms or with mod to very severe toxicity. #breastCancer #bcsm
https://t.co/2mKG4uIOkk

[Gustavo @gusviani]

🎙PBI ✖️WBI for early-stage #breastcancer: @JNCI_Now
📌Metanalysis:17,234 👥➡️14 RCTs & 6 observational
- 🥇endpoints: IBR,cosmetics & AEs
📊Findings:
👉5y IBR: PBI = WBI (RR 1.34, 95% CI 0.83—2.18)
👉10y IBR: PBI = WBI (RR 1.29, 95% CI 0.87—1.91)
👉Cosmesis:Insufficient evidence ⚠️
👉Acute AEs: ⬇️PBI✖️WBI
👉 Late AEs: NO sig #
👉IORT:⬆️IBR✖️WBI at 5, 10, >10 y⚠️
#radonc #TreatmentOption

[Krishan Jethwa @KrishanJethwa]

🔥🔥🔥 Brilliant take on the PROSPECT Trial

🔑🔑🔑 Points

🔑Patient selection (ie. Trial included favorable risk factors with exclusion of T4, N2, distal tumors not amenable to LAR, or within 3 mm of MRF)

🔑 Treatment intent (operative vs. watch & wait)

#ASCO23
👇🏼👇🏼👇🏼

[Memorial Sloan Kettering Radiation Oncology @MSK_RadOnc]

Listen to Dr. @LiorBraunstein of @MSKCancerCenter, the principal investigator for the @NRGonc “HERO” study, explain why he is excited for this potentially paradigm-shifting trial in HER-2 positive #breastcancer. #bcdm

https://t.co/o5mfwskYBD

[Memorial Sloan Kettering Radiation Oncology @MSK_RadOnc]

It's a Match! Welcome to @MSKCancerCenter #radonc!! 🥳
🙌Kathryn Hockemeyer MD, PhD
🙌Gideon Haber, MD
🙌Elisa Liu, MD
🙌Revathi Ravella, MD
🙌Alexander Terry, MD
🙌Shoshana Rosenzweig, MD
We're excited to have you join us in New York!
#Match2023 #radoncMatch2023

[Memorial Sloan Kettering Radiation Oncology @MSK_RadOnc]

🚨New in #AdvancesRO from @MSKCancerCenter #radonc: A tattoo-less setup with surface imaging (AlignRT) appears to be just as accurate for radiation alignment for #breastCancer #PBI --tattoos may not be necessary for #bcsm in the future. @LiorBraunstein
https://t.co/GtuDui21Ij

[Diana Roth O’Brien, MD MPH @drothens]

@seanmmcbride @blandro Cheers to all the fellow least adulty adults in every marriage. Tonight Hazel’s dinner was teensy snacks, pirates booty, and about 1000 raspberries 🤷🏼‍♀️

[Diana Roth O’Brien, MD MPH @drothens]

@HimanshuNagarMD 🙌🏻 happy new year to you!

[Fumiko Ladd Chino, MD, FASCO @fumikochino]

🚨#OncTwitter #HCWvsHunger RED ALERT🚨
🧪#Feedalizumab @tmprowell
☢️#RadiatePositivity
🩸#BadBlood @MaryCushmanMD
HAVE MERGED TO FORM SUPER GROUP #HemOnculus 💪🧬⚡️

🚨WE ARE WITHIN STRICKING DISTANCE OF #1.
Let's GOOOOOOOOO!!!!

[Memorial Sloan Kettering Radiation Oncology @MSK_RadOnc]

Did you know @MSKCancerCenter Dr @fumikochino is organizing the team #RadiatePositivity for the annual #HCWvsHunger competition? This year @HCWvsHunger has raised >$450k for food banks to combat #foodinsecurity over the holidays and the #radonc team specifically has raised >$22k!

[Kelsey Corrigan MD MPH @kelseycorrigan]

Inspired by @DrEmmaHolliday re: GI ASTRO recap, I gave a talk on high-yield BrCa abstracts from #ASTRO22. Too many great studies to include, but here are some highlights. Let me know your thoughts! And what did I miss? @IBCradiation @ChelainG @SFShaitelmanMD @PSchlembachMD 1/6